Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Fiedler
Roman
R
D002117:Calcitriol / Q000191:economics* / Q000627:therapeutic use; D004872:Ergocalciferols / Q000191:economics* / Q000627:therapeutic use; D005858:Germany; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006760:Hospitalization; D006801:Humans; D006887:Hydroxycholecalciferols / Q000191:economics* / Q000627:therapeutic use; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D018803:Models, Economic; D006435:Renal Dialysis / Q000009:adverse effects; D012107:Research Design; D015996:Survival Rate
D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; C084656:paricalcitol; D002117:Calcitriol; C008088:alfacalcidol